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Abstract
Several attempts have been made at systematically mapping protein-protein interaction, or 
“interactome” networks. However, it remains difficult to assess the quality and coverage of 
existing datasets. We describe a framework that uses an empirically-based approach to rigorously 
dissect quality parameters of currently available human interactome maps. Our results indicate that 
high-throughput yeast two-hybrid (HT-Y2H) interactions for human are superior in precision to 
literature-curated interactions supported by only a single publication, suggesting that HT-Y2H is 
suitable to map a significant portion of the human interactome. We estimate that the human 
interactome contains ~130,000 binary interactions, most of which remain to be mapped. Similar to 
estimates of DNA sequence data quality and genome size early in the human genome project, 
estimates of protein interaction data quality and interactome size are critical to establish the 
magnitude of the task of comprehensive human interactome mapping and to illuminate a path 
towards this goal.
The protein-protein interactome of an organism is the network formed by all protein-protein 
interactions that can occur in a range of physiologically relevant protein concentrations. 
Mapping protein-protein interactions is crucial, albeit not sufficient, for unraveling the 
dynamic aspects of cellular networks, including when, where, and for what purpose protein 
interactions do occur in vivo1. Currently available human protein-protein interactome maps 
have been derived using (i) high-throughput yeast two-hybrid (HT-Y2H)2,3, (ii) HT co-
affinity purification followed by mass spectrometry4, (iii) curation of published low-
throughput experiments5–10, or (iv) computational predictions11,12. Despite a few 
attempts2,3,13,14, it remains difficult to accurately estimate the quality of these interactome 
maps and how far away we are from a complete map of the human interactome.
Differentiation between sets of protein pairs that can interact (biophysical interactions) and 
do interact (biological interactions) is only possible with reliable biophysical interactome 
maps. What proportion of currently available interactome maps represents true biophysical 
interactions and what proportion represents artifacts? Are the interactions provided by 
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curated low-throughput experiments superior in quality to those obtained by HT strategies, 
as suggested previously15–17? Do the currently available interactome maps represent a 
significant or a negligible fraction of the human biophysical interactome? Here we provide 
insights that are crucial for developing a strategy for comprehensive interactome mapping, 
i.e., for estimating the size of the human interactome and thus an endpoint to the project, and 
for selecting suitable technologies, a realistic timeline and a funding model to achieve this 
goal.
Previous attempts to assess the quality of interactome maps for human13,14,18 or other 
species13,15,18–23 relied on measuring (i) the extent to which interacting proteins share other 
biological attributes, e.g., co-expression, or (ii) the extent to which different maps of the 
same interactome share common interactions. Both approaches suffer several inherent 
limitations. Methods that evaluate the quality of interactions with respect to mRNA co-
expression22,23 are systematically biased against true biological interactions between 
proteins whose mRNAs are not necessarily correlated or are even anti-correlated in 
expression. Since available annotations for protein function and localization are far from 
comprehensive, lack of evidence for co-localization of a given pair of proteins does not 
imply that the interaction observed between these proteins is an artifact. Methods based on 
measuring the extent of overlap between two interactome maps13,20,21 require that the 
corresponding datasets be derived from identical or similar assays. Existing analyses have 
not always fulfilled this requirement13. Most existing methods for quality assessment do not 
distinguish between the multiple sources of false negatives and false positives associated 
with any interactome mapping strategy. For instance, those interactions missed by a single 
screen of an assay but identifiable after multiple screens must be distinguished from the 
interactions that would never be identified by that assay even after a saturating number of 
screens.
Here we developed a framework to estimate various quality parameters associated with 
currently used protein-protein interaction assays, namely screening completeness, assay 
sensitivity, sampling sensitivity and precision. We generated empirical data to rigorously 
dissect these quality parameters, without relying on correlation with other biological 
attributes. Combining these parameters provides an estimate of the size of the human binary 
biophysical interactome and projects a path towards the completion of its mapping.
RESULTS
An interaction mapping framework
To accurately assess the quality of a given interactome map, we need to consider every 
possible source of false negatives (true interactions missing) and false positives (spurious 
pairs reported) associated with the assay used to generate the map. Our framework considers 
four parameters to estimate quality: “screening completeness”, “assay sensitivity”, 
“sampling sensitivity” and “precision” (Fig. 1).
“Screening completeness” is the fraction of the total possible space of open reading frame 
(ORF) pairs that is tested to generate a given interactome map (Fig. 1a). Since currently 
available ORF resources3,24 only allow proteome-wide investigations of one protein isoform 
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per gene, we ignore isoforms encoded by alternatively spliced transcripts here. For example, 
if we assume that the human genome consists of 22,500 protein-coding genes (N = 22,500 × 
22,500/2 protein pairs), then the screening completeness of CCSB-HI12, a proteome-scale 
HT-Y2H effort that tested n = 7,000 × 7,000/2 human protein pairs, is n/N, or ~10%.
“Assay sensitivity” is the fraction of all biophysical interactions that can possibly be 
identified by an assay performed under a specific set of experimental conditions (Fig. 1b). 
For example, a given HT-Y2H assay may be unable to detect interactions involving specific 
types of membrane proteins or requiring post-translational modifications that do not occur in 
yeast cells.
“Sampling sensitivity” is the fraction of all identifiable interactions that are found in a single 
trial of an assay performed under a specific set of experimental conditions (Fig. 1c). When 
testing tens if not hundreds of millions of protein pairs in any space of pair-wise 
combinations, it might be necessary to sample that space multiple times to report all 
identifiable interactions.
Lastly, “precision” is the fraction of observed pairs in an interactome dataset that are true 
positives (Fig. 1d). False positive pairs reflect technical artifacts that erroneously score 
positive in a given assay performed under a specific set of experimental conditions. We 
distinguish between two types of artifactual pairs, “stochastic false positives”, which are 
observed in only one or a few trials of an assay and “systematic false positives”, which are 
observed in many or all trials.
Estimation of assay sensitivity
Estimation of the assay parameters described above requires reference sets of positive and 
negative interacting pairs. To compile a positive reference set of high-confidence human 
binary protein-protein interactions we started with interactions curated from the literature 
(“literature curated” or LC interactions) and from these, we chose 188 pairs present in our 
human ORFeome v1.1 clone collection24 that are supported by the greatest number of 
publications and curated by the highest number of databases. Systematic recuration of all 
publications thought to support these 188 protein pairs25 verified 107 direct binary 
interactions that involve human proteins and that are supported by multiple publications. 
Ninety-two of these interactions involve full-length proteins and constituted our Homo 
sapiens Positive Reference Set version 1 or “hsPRS-v1” (Fig. 2a and Supplementary Table 1 
online). Proteins involved in the 92 hsPRS-v1 interactions exhibit broad cellular localization 
(Fig. 2b), suggesting that they are representative of the entire human proteome. It is 
impossible to generate a set of negative interacting pairs with absolute confidence. So we 
compiled a surrogate Random Reference Set (“hsRRS-v1”) of 188 protein pairs chosen 
randomly from the space of all ORFeome v1.1 pairs after excluding known interactions (Fig. 
2c).
PRS and RRS pairs can be used to experimentally calibrate conditions of an assay to achieve 
an optimal trade-off between the fraction of PRS and RRS pairs reporting positive26. We 
measured the fraction of hsPRS-v1/hsRRS-v1 pairs scoring positive across a range of 
experimental and scoring conditions of a stringent version of the Y2H system (Y2H-CCSB)2 
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and the mammalian protein-protein interaction trap assay (MAPPIT)27 (Supplementary 
Table 2 online and Fig. 2d,e).
The results observed with the hsPRS-v1 and hsRRS-v1 pairs for Y2H-CCSB confirm that 
the specific experimental conditions used in generating our first human interactome map, 
CCSB-HI12, reflected good assay design. We also derived suitable experimental conditions 
for the MAPPIT assay. Under these experimental conditions we estimated the assay 
sensitivity of Y2H-CCSB and MAPPIT to be 17% and 21% respectively (Fig. 2f and 
Supplementary Table 3 online). Using a larger, more recently updated set of ~1,500 LC 
interactions that are supported by multiple publications we estimated an assay sensitivity of 
20% for Y2H-CCSB, consistent with our hsPRS-v1-based estimate. Y2H-CCSB and 
MAPPIT recovered partially overlapping sets of hsPRS-v1 interactions. Of the hsPRS-v1 
pairs 29% (27/92) were reported by at least one assay, and of these, 26% (7/27) were 
detected by both assays (Figs. 2f,g). That 74% (20/27) of positive hits are specific to a single 
assay reflects the complementarities between the two assays.
We estimated the false positive rate (rate of scoring hsRRS-v1 pairs positive) of Y2H-CCSB 
and MAPPIT to be < 0.5% and 2% respectively (Fig. 2f and Supplementary Table 4 online). 
The results of testing hsRRS-v1 pairs by Y2H-CCSB do not permit a direct and reasonable 
estimate of the false discovery rate associated with the CCSB-HI1 dataset. The millions of 
pairs tested by Y2H-CCSB in the HT screen leading to the generation of CCSB-HI1 consist 
mostly of non-interacting pairs, so the number of non-interacting pairs tested in the HT-Y2H 
screen is orders of magnitude higher than the size of hsRRS-v1. Consequently, small 
changes in the hsRRS-v1-based estimate of the false positive rate of Y2H-CCSB can have a 
large effect on the resulting estimate of the false discovery rate of CCSB-HI1. Rather than 
using the Y2H-CCSB experiments on the hsRRS-v1 pairs, we instead used two alternate and 
independent approaches to estimate the false discovery rate of our Y2H-CCSB assay: (i) 
retesting Y2H-CCSB interactions in MAPPIT and (ii) modeling repeated screens of Y2H-
CCSB (see below).
Precision of existing human interactome datasets
We estimated the precision of the two existing HT-Y2H human interactome datasets, CCSB-
HI12 and MDC-HI13, and a low-throughput LC human interactome dataset2 by measuring 
the extent to which a subset of 188 positive pairs chosen randomly from each dataset 
(Supplementary Table 1) retested in MAPPIT. To do so, we first benchmarked the 
performance of a dataset in MAPPIT experiments against (i) the false positive rate of 
MAPPIT and (ii) the false negative rate of MAPPIT. We estimated these benchmarks by 
evaluating the fraction of hsRRS-v1 and hsPRS-v1 pairs reporting positive by MAPPIT, 
respectively. The results with the hsRRS-v1 pairs provided an estimate of MAPPIT’s false 
positive rate that is sufficiently resolved for estimating false discovery rates of the various 
interactome datasets, since the size of the hsRRS-v1 is similar to the size of each of the three 
different interactome datasets tested. Relative to the proportion of hsPRS-v1 and hsRRS-v1 
pairs scoring positive (21% and 2%, respectively), the fractions of pairs that scored positive 
in the three datasets were: LC, 8%; MDC-HI1, 10%; and CCSB-HI1, 27% (Fig. 3a and 
Supplementary Table 4).
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This analysis needs to be adjusted for potential dataset biases. First, we minimized the effect 
due to differences between the sequences of the clones originally used to report the 
interactions and sequences of the full-length clones used here. We considered only pairs for 
which the proteins originally used were described as full-length (FL) or, whenever 
identifiable, pairs for which the isoforms originally used were the same (“Same”) as the ones 
used here. Second, since the CCSB-HI1 and MDC-HI1 datasets were each described in a 
single publication, we compared them to the subset of LC interactions also supported by a 
single publication (“Single”), which represents most currently available literature-curated 
interaction information25. Including interactions supported by multiple publications in the 
LC dataset would be circular since our hsPRS-v1 benchmark was derived from LC 
interactions supported by multiple publications. Lastly, to account for the moderate bias of 
MAPPIT in detecting Y2H-supported (“Y2H”) interactions, we considered the subset of 
hsPRS-v1 and LC interaction pairs supported by at least one Y2H experiment in the 
corresponding curated publications (Supplementary Data 1 and Supplementary Table 5 
online). Based on these consolidated datasets, 34% of Y2H-supported hsPRS-v1 pairs (PRS-
Y2H) and 2% of hsRRS-v1 pairs scored positive. Relative to this, the fractions of pairs that 
scored positive in the three subsets of protein pairs were: LC (Single, FL, Y2H), 10%; 
MDC-HI1 (Same, FL), 31%; and CCSB-HI1 (Same, FL), 27% (Fig. 3b). Thus, the two HT-
Y2H datasets performed comparably to the PRS-Y2H pairs in MAPPIT, while the literature-
curated interactions supported by a single publication performed poorly. Given the fraction 
of PRS-Y2H pairs and hsRRS-v1 pairs scoring positive by MAPPIT, the precision of each 
of the three datasets can be computed as: LC (Single, FL, Y2H), 25%; MDC-HI1 (Same, 
FL), 83%; and CCSB-HI1 (Same, FL), 79% (Fig. 3c and Supplementary Table 3).
Sampling sensitivity and stochastic false discovery rate
To estimate sampling sensitivity and the number of screens required to achieve saturation, 
we repeated four Y2H-CCSB screens (“repeat screens”) in a defined search space of 1,822 
DB-Xs (or “baits”; representing 1,744 unique genes) against 1,796 AD-Ys (or “preys”; 
representing 1,752 unique genes), representing approximately three million pair-wise 
combinations (Supplementary Table 6 online). We developed a probabilistic model that 
considered the search space of three million protein pairs to be a mixture of true biophysical 
interactions and non-interacting pairs. Using a Bayesian approach, our model estimated (i) 
the fraction of all identifiable true biophysical interactions found in one, two, or a saturating 
number of screens and (ii) the fraction of non-interacting pairs erroneously detected in a 
screen. In short, our approach estimated distributions of values of the above parameters that 
fit the experimental results observed in the repeat screens.
Out of the three million pair-wise combinations tested, the four Y2H-CCSB repeat screens 
together reported 240 protein-protein interactions (Supplementary Tables 7 and 8 online). Of 
these interactions 49% appeared in multiple screens. The total number of new interactions 
identified after successive screens showed an increasing trend, indicating that more 
interactions would be found with additional screens (Fig. 3d). Based on our model, we 
estimated that the sampling sensitivity per screen is 45% and that after a saturating number 
of screens, Y2H-CCSB can identify 71 interactions per million pairs tested (Fig. 3e). 
Approximately six screens are needed to reach 90% saturation. Importantly, the number of 
Venkatesan et al. Page 6
Nat Methods. Author manuscript; available in PMC 2010 May 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
single hits (interactions found in only one out of several screens) decreases while the 
contribution of multiple hits dominates after multiple screens. Adjusting for these repeat 
screens being done in only one Y2H configuration (bait-prey vs. prey-bait), we estimated 
that upon testing both configurations, the sampling sensitivity per screen is 53% and that 
after a saturating number of screens, Y2H-CCSB can identify 118 interactions per million 
pairs tested (Supplementary Table 3).
Our model estimated that approximately eight out of every million non-interacting pairs 
tested falsely report positive in Y2H-CCSB. Consequently, our model estimated a stochastic 
false discovery rate of 12%, meaning that 12% of the interactions reported in a single Y2H-
CCSB screen correspond to stochastic false positives. Since the MAPPIT experiments (Fig. 
3c) evaluate the union of systematic and stochastic false positives in a given dataset and 
estimated an overall false discovery rate of 21% for CCSB-HI1, we deduce a systematic 
false discovery rate of 14% (Supplementary Methods online).
The MAPPIT experiments show that existing human HT-Y2H maps have high precision. 
However, the fraction of CCSB-HI1 and MDC-HI1 interactions common to both maps is 
small although statistically significant, only 6% and 2%, respectively (P = 10−18, 
Supplementary Data 2 and Supplementary Fig. 1 online). Our results indicate that low 
sampling sensitivity and differences in assay sensitivity likely account for the small overlap.
Estimation of the size of the human interactome
We estimated four important parameters associated with the quality of human binary 
interactome maps (Fig. 1). For the Y2H-CCSB assay evaluated here, we computed the 
screening completeness of the repeat screens as ~1%; the hsPRS-v1 experiment estimated an 
assay-sensitivity of ~17% (Fig. 2f); the model of the repeat screens estimated a sampling 
sensitivity of ~53% (Fig. 3e); and the MAPPIT experiment estimated a precision of ~79% 
(Fig. 3c). We also estimated the variation of these estimates associated with sampling 
(Supplementary Table 3). Integrating these parameters, we predict that the entire human 
interactome, excluding splice variant complexity, contains approximately 74,000–200,000 
binary biophysical interactions (Table 1).
Interacting protein pairs and shared functional annotation
A statistically significant fraction (P < 10−3) but not all of the interacting protein pairs in 
CCSB-HI1 and MDC-HI1 showed correlation for shared functional annotations compared to 
random expectation (Fig. 4). Given the high technical quality of these datasets demonstrated 
here, interacting pairs that do not correlate with known functional annotations could be: (i) 
promising candidates for biological discovery, particularly true biological interactions that 
involve proteins currently lacking adequate functional annotations; or (ii) true biophysical 
interactions that do not occur physiologically. We call this second class “pseudo-
interactions” by analogy to pseudo-genes. Pseudo-interactions could correspond to ancient 
biological interactions that have evolved to lose physiological relevance and provide 
interesting insights into the evolution of the interactome.
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DISCUSSION
Several previous studies have estimated the precision of existing maps or the size of 
interactomes13–15,18,20–23,28. Our empirical framework addresses limitations of these 
studies (detailed discussion in Supplementary Data 3 online). Methods that rely on 
correlation with other biological attributes to estimate precision of interactome maps (i) 
often use as benchmark, LC interaction datasets, which are sociologically biased, (ii) assume 
that knowledge of biological attributes such as Gene Ontology functional annotation is 
complete and unbiased, and (iii) are inherently constrained by pre-existing paradigms 
regarding the expectation for interacting protein pairs to share biological attributes. 
Approaches based on analyzing the extent of overlap between interactome maps13,20,21 
suffer specific limitations in their implementations such as comparing maps that were not 
derived using the same assay, or using LC datasets as a reference set, which may not be 
appropriate given a potentially higher false positive rate than previously anticipated (Fig. 
3c)25. Earlier studies also failed to consider one or more of the parameters that influence 
interactome map quality, i.e., completeness, systematic false discovery rate, stochastic false 
discovery rate, assay sensitivity and sampling sensitivity, which could in turn significantly 
affect estimates of interactome size. All these limitations together may have led to 
overestimated false discovery rates for HT-Y2H human interactome maps.
Our framework overcomes these limitations by (i) considering every possible source of false 
negatives and false positives, (ii) using a high-quality reference set requiring interactions to 
be supported by multiple publications and to pass additional recuration, (iii) assessing false 
discovery rates directly using information from independent protein-protein interaction 
assays and (iv) comparing overlaps between four homogeneously-derived repeat screens to 
assess the sampling sensitivity and stochastic false discovery rate of Y2H-CCSB. Close 
attention to these parameters will be vital to design the strategy, e.g., number of screens and 
types of assays to use, for future interactome mapping projects.
The hsPRS-v1 and hsRRS-v1 provide hundreds of experimentally testable clone pairs of 
positive and random reference sets for binary protein-protein interactions. Previous assays 
typically relied on testing one or a few positive control pairs and a few or no random control 
protein pairs. Though our reference sets are a first version and will be improved, they mark a 
substantial effort towards the standardized calibration of binary interaction mapping assays, 
an objective that has not been previously achieved systematically.
Although LC datasets are commonly perceived to be of better quality than datasets 
generated with HT technologies15–17, the results of our MAPPIT experiments indicate that 
stringent implementations of HT-Y2H assays produce interaction datasets with technical 
quality at least as good if not superior to low-throughput LC interactions (Fig. 3c). These 
results substantiate previous computational analyses of human29 and yeast30 interactome 
maps. Large-scale curation of the primary literature is challenging and may have higher 
error rates than previously anticipated25. HT interactome mapping strategies have several 
advantages over low-throughput strategies: (i) since defined search spaces are used, 
information about positives (pairs observed to interact) as well as negatives (pairs not 
observed to interact) is available; (ii) experiments are standardized therefore well-controlled, 
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comparable and scalable; (iii) cost-efficient strategies can be developed; and (iv) HT 
strategies are less sociologically biased than low-throughput experiments.
Implementation of our framework can be improved in various ways. The statistical power of 
the analyses can be increased by testing more PRS interactions, by repeatedly screening 
larger search spaces, or by using additional independent assays for measuring precision. Our 
current implementation does not consider multiple splice isoforms per gene, so we most 
likely underestimated the interactome size. Additional modifications to the framework will 
be required to thoroughly analyze non-binary co-complex membership maps such as those 
generated by HT co-affinity purification followed by mass spectrometry4. While more 
refined estimates can be made with future enhancements, the central concepts and overall 
approach are in place for design and comprehensive evaluation of any interactome mapping 
assay. Recently, our group has developed an interaction toolkit consisting of four 
independent assays to evaluate the quality of any protein interaction dataset26. Ongoing 
technological advancements related to assay automation and cost reduction will enable 
testing of expanded versions of the PRS and thousands (rather than hundreds) of Y2H, LC 
and other interactions using these assays.
Similar to estimates of the number of protein-encoding genes in the human genome, 
~14,000–300,000 in the early 1990s31, empirical sizing of the interactome is critical to 
establish the complexity of the network and to estimate how far we are from a complete 
human interactome map. Assuming one splice isoform per gene, we predict that the size of 
the human interactome is ~130,000 interactions. This confirms two previous estimates of 
human interactome size, which ranged from 150,000–370,000 interactions2,13. Out of 
~23,000 currently reported human interactions (a combination of ~17,000 LC interactions 
and ~6,000 HT-Y2H interactions), our measurements indicate that ~10,000 (~42%) are true 
binary physical interactions (Supplementary Data 4 online). Thus, the fraction of 
interactions identified so far represents ~8% of the full interactome.
With 22,500 protein-coding genes, nearly 250 million protein pairs need to be tested 
individually, clearly requiring unbiased, systematic and cost-effective HT approaches. 
Interactome mapping is gradual: six screens are necessary to reach 90% saturation with 
Y2H-CCSB. No single assay offers complete assay sensitivity. The fraction of protein-
protein interactions detectable by the specific version of HT-Y2H used here (“Y2H-CCSB”) 
is ~17%. Combining different versions of the Y2H system and using increased expression of 
both hybrid proteins can increase this proportion to ~40% (data not shown and Braun et al.
26). Still, comprehensive mapping of the interactome will require the development of 
additional HT versions of MAPPIT and other assays26.
The potential impact on biology of a complete and reliable biophysical protein interaction 
map cannot be overestimated. Our results offer a quantitative roadmap in this direction, 
uncovering both the magnitude of the task ahead as well as the potential roadblocks.
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METHODS
The Y2H-CCSB experiments were performed as described2 with minor changes. MAPPIT 
experiments were performed essentially as described32. Mathematical modeling of the 
repeat screens was performed using a Bayesian approach. All parameters observed from 
either the experimental data or from the mixture model were used as inputs into a Monte 
Carlo simulation to calculate the corresponding magnitudes of corresponding numbers 
reported in the text. Detailed descriptions of all datasets and methods can be found in 
Supplementary Methods online.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Conceptual framework for interactome mapping
The concepts of “screening completeness” (fraction of all pair-wise protein combinations 
tested), “assay sensitivity” (fraction of all biophysical interactions identifiable by a given 
assay), “sampling sensitivity” (fraction of all identifiable interactions that are detected in a 
single trial) and “precision” (fraction of pairs reported by a given assay that are true 
positives) can be estimated independently and combined to empirically estimate the size of 
binary interactomes. PRS: the set of positive reference set interactions; RRS: the random 
reference set. Solid black lines in a given network graph represent true biophysical 
interactions present in that network, dashed lines represent true biophysical interactions 
missing in that network, and solid colored lines represent biophysical artifactual pairs 
present in that network.
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Figure 2. Assay sensitivity and background positive rate of binary interactome mapping assays
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(a) How positive reference set interactions were chosen from among the interactions 
available in the curated literature of low-throughput experimentally derived interactions 
(LC). (b) How random reference set pairs were chosen from among the possible pairs in our 
human ORFeome v1.1 clone collection24. (c) Distribution of cellular location of proteins 
making up the positive and random reference sets. (d) Assay sensitivity (fraction of hsPRS-
v1 pairs scoring positive) and background positive rate (fraction of hsRRS-v1 pairs scoring 
positive) of the Y2H-CCSB assay based on varying experimental and scoring conditions, 
including the use of an alternate protocol (Supplementary Methods). We did not use the 
results of testing the hsRRS-v1 pairs here to estimate the false discovery rate of the Y2H-
CCSB assay due to limited sample size. (e) Assay sensitivity and background positive rate 
of the MAPPIT assay upon varying experiment-to-control-ratio (ECR) scores 
(Supplementary Methods). (f) Upper panel: assay sensitivity and background positive rate of 
Y2H-CCSB and MAPPIT under the specific experimental conditions used (Supplementary 
Methods). For Y2H-CCSB, the fraction of hsPRS-v1 pairs scoring positive in at least one 
configuration and in both pair-wise mating experiments is depicted. This condition reflects 
the assay sensitivity of the specific experimental and scoring conditions of Y2H-CCSB used 
to generate CCSB-HI12. Lower panel: Venn diagram of hsPRS-v1 pairs scoring positive in 
the two assays. (g) Results of testing each hsPRS-v1 pair and each hsRRS-v1 pair using 
Y2H-CCSB and MAPPIT. Blue or yellow shaded squares represent protein pairs scored 
positive by a given assay.
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Figure 3. Precision and sampling sensitivity in interactome datasets
(a) Comparison of interactome datasets by comparing the rate of observing a positive by 
MAPPIT given a positive in the dataset. (b) Interactome datasets were further compared 
after removing various biases by considering interactions originally derived using full-length 
(FL) proteins and using Y2H assays. (c) Precision of each tested dataset computed by 
accounting for the rate of detecting hsRRS-v1 pairs and Y2H-supported hsPRS-v1 pairs by 
MAPPIT in b. Error bars represent estimated standard deviation of the mean based on a 
Monte Carlo simulation of scores observed in a given assay. (d and e) Sampling sensitivity 
and Y2H-CCSB repeat screens. Bars filled with white represent protein pairs uncovered in 
only one screen and progressively dark shades of blue represent protein pairs reported in 
increasing number of multiple screens. (d) Data observed in Y2H-CCSB repeat screens 
indicating the total number of positive pairs reported after one, two, three or four screens. (e) 
Predicted saturation curve of the number of uncovered interactions against the number of 
screens for Y2H-CCSB after modeling the data in d and assuming a single isoform per gene 
in the respective tested spaces.
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Figure 4. Correlation of interacting pairs for shared functional annotation
Correlation of interacting pairs in CCSB-HI1 and MDC-HI1 interactome maps for specific 
shared Gene Ontology functional annotations. P-values indicate the probability of observing 
such a correlation by chance (compare black bars to white bars) computed using Fisher’s 
exact test. Analysis was performed on MDC-HI1 and CCSB-HI1 interactions reported using 
full-length ORFs.
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